Allorion Therapeutics Announces Exclusive Option, Global License Agreement With AstraZeneca

Palo Alto – January 2, 2024 – Cooley advised Allorion Therapeutics, a US- and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, on its exclusive option and global license agreement with AstraZeneca to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor as a potential new treatment for advanced EGFR-mutant non-small-cell lung cancer. Lawyers Marya Postner, Brendan Haberle and Yiming Liu led the Cooley team advising Allorion.

Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. Allorion is eligible to receive upfront and near-term payments of up to $40 million, additional development and commercial milestone payments of more than $500 million, and tiered royalties on net sales worldwide.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.